Silvia Hanselmann

508 total citations
10 papers, 405 citations indexed

About

Silvia Hanselmann is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Silvia Hanselmann has authored 10 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Silvia Hanselmann's work include Prostate Cancer Treatment and Research (7 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (4 papers). Silvia Hanselmann is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (4 papers). Silvia Hanselmann collaborates with scholars based in Switzerland and Germany. Silvia Hanselmann's co-authors include Markus Borner, Aron Goldhirsch, Daniel Dietrich, Richard Herrmann, Martin Wernli, Bernhard C. Pestalozzi, Rudolf Morant, R. Morant, Peter Brauchli and Arnaud Roth and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Silvia Hanselmann

10 papers receiving 393 citations

Peers

Silvia Hanselmann

ONCOL

PRM

SURGE

HEPAT

Jeffrey Patton United States

J Lokich United States

Anna Świeboda-Sadlej Poland

Ramón Barceló Spain

Wayne Saville United States

Manali Bhave United States

E Piana Italy

M. Karina Greece

William Leslie United States

Wanda Honeycutt United States

Jeffrey Patton United States

Silvia Hanselmann

203 ×0.8

ONCOL

202 ×0.9

PRM

68 ×1.0

SURGE

32 ×0.5

HEPAT

30 ×0.6

Citations per year, relative to Silvia Hanselmann Silvia Hanselmann (= 1×) peers Jeffrey Patton

Countries citing papers authored by Silvia Hanselmann

Since Specialization

Citations

This map shows the geographic impact of Silvia Hanselmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Hanselmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Hanselmann more than expected).

Fields of papers citing papers by Silvia Hanselmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Hanselmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Hanselmann. The network helps show where Silvia Hanselmann may publish in the future.

Co-authorship network of co-authors of Silvia Hanselmann

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Hanselmann. A scholar is included among the top collaborators of Silvia Hanselmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Hanselmann. Silvia Hanselmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Leupin, Nicolas, Jan C. Schuller, Max Solenthaler, et al.. (2010). Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leukemia & lymphoma. 51(4). 613–619. 6 indexed citations

Morant, R., Jürg Bernhard, D. Dietrich, et al.. (2004). Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial. British Journal of Cancer. 90(7). 1312–1317. 29 indexed citations

Studer, Urs E., D. Hauri, Silvia Hanselmann, et al.. (2004). Immediate Versus Deferred Hormonal Treatment for Patients With Prostate Cancer Who Are Not Suitable for Curative Local Treatment: Results of the Randomized Trial SAKK 08/88. Journal of Clinical Oncology. 22(20). 4109–4118. 73 indexed citations

Morant, R., S.‐F. Hsu Schmitz, J. Bernhard, et al.. (2002). Vinorelbine in androgen-independent metastatic prostatic carcinoma—a phase II study. European Journal of Cancer. 38(12). 1626–1632. 25 indexed citations

Borner, Markus, Daniel Dietrich, Roger Stupp, et al.. (2002). Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer. Journal of Clinical Oncology. 20(7). 1759–1766. 137 indexed citations

Schmid, Hans‐Peter, Jürg Bernhard, Axel Semjonow, et al.. (2001). Prostate specific antigen in as a dynamic model in advanced prostate cancer.. PubMed. 20(6D). 4985–7. 1 indexed citations

Morant, R., J. Bernhard, Rudolf Maibach, et al.. (2000). Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Annals of Oncology. 11(2). 183–188. 38 indexed citations

Jungi, W. F., et al.. (1998). Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Supportive Care in Cancer. 6(5). 462–468. 28 indexed citations

Borner, M., M. Castiglione, M. Bacchi, et al.. (1998). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Annals of Oncology. 9(5). 535–541. 45 indexed citations

10.

Schmid, Hans‐Peter, Rudolf Maibach, J. Bernhard, et al.. (1997). A Phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Cancer. 79(9). 1703–1709. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact